Comanaging Cases of RR/MM in Patients Receiving CAR T

Video content above is prompted by the following:

• Describe your institution’s approach to the comanagement and comonitoring of patients receiving CAR T-cell therapy, particularly in the transition back to the community setting.
• Dr Abdallah to ask Dr Kort: Can you share any specific strategies or tools your institution utilizes to facilitate seamless transitions of care between the academic center and community practices for patients receiving CAR T-cell therapy?
• Dr Abdallah to ask Dr Mahmoudjafari: What are the most common challenges you have encountered in the CAR T referral process, and how have you addressed them at your institution?
• Dr Abdallah to ask Dr Mushtaq: What advice would you provide to community physicians regarding the appropriate timing and preparation for referring patients for CAR T therapy?
• Dr Abdallah to ask Dr Kort: Can you share any examples of successful collaborations between your academic center and community practices in the context of CAR T therapy for multiple myeloma?
• Dr Abdallah to ask Dr Mahmoudjafari: What are the most important lessons your institution has learned in the integration of CAR T therapy into the multiple myeloma treatment landscape?